German court overturns Halozyme injunction blocking Merck's Keytruda SC launch
HALO•A German appeals court overturned a December 2025 preliminary injunction blocking Merck’s Keytruda SC launch in Germany. Halozyme plans to immediately file a German patent infringement lawsuit seeking permanent relief.
1. Appeals court ruling
A German appeals court overturned a December 2025 preliminary injunction that had blocked Merck’s Keytruda SC launch in Germany. Halozyme Therapeutics plans to immediately file a German patent infringement lawsuit against Merck, seeking permanent relief.
2. Other patent dispute
A separate Dutch patent ruling in October 2026 prohibited Merck’s European marketing authorization holder from infringing through Keytruda SC in eight countries. Halozyme said the MDASE patent dispute will not affect ENHANZE licensing rights or revenue because the patents are distinct.




